1、 : (RA) C- (CRP) , - - -1 (IL-1) IL-6 : 120 , 60 , 7.5 mg/ , 1 /d; , 2 / , 3 /d , , , 3 /d; , , , 3 /d 4 , ; (DAS28) , (SDAI) , (HAQ) ; (ESR) , CRP, (RF) , TNF- -1 IL-6 ; : ACR20, ACR50 91.67%, 56.67%, 68.33%, 36.67% (P2.6 DAS285.1 1.2.2 2011 7 , (1) , , ; (2) , , (1) , ; (2) , ; (3) , , , , , 1 1.3
2、 (1) ACR RA , , X ; (2) ; (3) ; (5) 1865 , ; (6) , 1.4 (1) RA RA ; ; (2) 1 ; (3) ; (4) ; (5) , , ; (6) ; (7) ; (8) , 1.5 7 , ( , H20133188) , 7.5 mg/ , 1 /d; ( , H20055058) , 2 / , 3 /d , ( , H19990291) , , , , , 3 /d , ( , Z20060016) , 4 , 3 , , , , , , , , , 3 /d 4 1.6 (1) , VAS , , , 4 , 0, 1, 2,
3、 3 ; 1 (2) , DAS286; 1 (3) (SDAI) 8, (28) (28) (VAS , 100 mm) (VAS , 100 mm) C- , SDAI; 1 (4) (HAQ) 8; 1 (5) , (RF) , (ESR) , C- (CRP) , -1 (IL-1) , IL-6 - - 1 , ( , 20150311 2015102A) (6) , ( ) , ;00.49 , 0.52.99 , 3.05.99 , 6.08.0 9; ( ) , 1.7 RA ACR 10, ACR20, ACR50 ACR70 ACR20 5 3 5 3 5 3 1.8 SP
4、SS 20.0 , , t ; x , Ridit , P0.05 2 2.1 ACR ACR20, ACR50 91.67%, 56.67%, 68.33%, 36.67% (P0.05, P0.01) , ACR70 , , 1 2.2 , (P0.01) ; , (P0.01) ; , (P0.05, P0.01) , 2 3 1 Table 1 Comparison of clinical efficacy in two groups 2 mparison n=60) 3 Table 3 Comparison of regression of symptoms in two group
5、s before and after treatment 2.3 , DAS28, SDAI, HAQ , ESR CRP (P0.01) ; DAS28, SDAI, HAQ , ESR CRP , (P0.01) , 4 4 of main symptoms in two groups before n=60) 2.4 RF, IL-1, IL-6 TNF- , RF, IL-1, IL-6 TNF- (P0.01) ; RF, IL-1, IL-6 TNF- , (P0.01) , 5 5 RF, IL-1, IL-6 TNF- n=60) Table 5 Comparison of c
6、hanges in RF, IL-1, IL-6 and TNF- 2.5 Ridit , , 6 6 Table 6Comparison of response caused by skin irritation in two groups 3 RA , , , , RA , , , 11-12 NSAIDs, NSAIDs , , , , , , NSAIDs 13 , , , , 14 , , , , ; , 7,15 RA , , 16 , , , , , , , 2 , , , , , , , , 17 , , , , , , , , , , , , , , RA IL- - , 18; p38 MAPK, JNK , NO , , , 19 , , 20 , , DAS28, SDAI, HAQ , ESR CRP , RF, IL-1, IL-6 TNF- , ACR20, ACR50 91.67%, 56.67%, 68.33%, 36.67%, RA , , , , , ; , , , , RA , , , , ,
